CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Neurocrine Biosciences, Inc. - NBIX CFD

126.10
0.45%
Market Trading Hours* (UTC) Open now
Closes on Monday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.20
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024124 %
Charges from full value of position ($-4.58)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024124%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001901 %
Charges from full value of position ($0.36)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001901%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.7
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 126.78
Open 126.16
1-Year Change 7.89%
Day's Range 125.89 - 127.6
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 29, 2024 126.50 0.47 0.37% 126.03 126.95 124.97
Nov 27, 2024 126.40 -0.50 -0.39% 126.90 127.46 125.18
Nov 26, 2024 127.83 0.93 0.73% 126.90 128.06 123.31
Nov 25, 2024 126.89 1.14 0.91% 125.75 127.70 124.61
Nov 22, 2024 125.25 0.30 0.24% 124.95 126.85 123.96
Nov 21, 2024 124.98 2.32 1.89% 122.66 125.90 121.68
Nov 20, 2024 122.88 3.84 3.23% 119.04 123.67 118.80
Nov 19, 2024 118.72 2.48 2.13% 116.24 119.67 114.59
Nov 18, 2024 117.34 0.91 0.78% 116.43 118.18 115.98
Nov 15, 2024 117.38 -3.37 -2.79% 120.75 122.29 117.00
Nov 14, 2024 122.36 -3.02 -2.41% 125.38 125.38 122.03
Nov 13, 2024 125.47 -1.53 -1.20% 127.00 127.74 125.06
Nov 12, 2024 126.96 0.61 0.48% 126.35 128.09 125.24
Nov 11, 2024 127.09 2.12 1.70% 124.97 129.38 124.53
Nov 8, 2024 125.35 1.65 1.33% 123.70 126.18 123.44
Nov 7, 2024 123.90 -0.55 -0.44% 124.45 126.42 123.23
Nov 6, 2024 125.23 1.12 0.90% 124.11 126.36 121.88
Nov 5, 2024 121.41 2.46 2.07% 118.95 121.81 118.88
Nov 4, 2024 120.43 -0.86 -0.71% 121.29 122.24 119.37
Nov 1, 2024 121.86 2.14 1.79% 119.72 122.47 119.72

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Neurocrine Company profile

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.

Industry: Bio Therapeutic Drugs

12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US

News

SHIB cryptocurrency logo, showing a cartoon Shiba Inu dog on a coin, over a golden orange background with circuit board graphics detail

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

16:41, 28 November 2024
Gold bars on a black background with a diagram

Gold price predictions for the next five years: Third party data round up

Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

15:17, 18 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024

People also watch

Oil - Crude

67.96 Price
-0.160% 1D Chg, %
Long position overnight fee 0.0022%
Short position overnight fee -0.0241%
Overnight fee time 22:00 (UTC)
Spread 0.040

ETH/USD

3,607.21 Price
-2.370% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

95,664.45 Price
-2.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,640.33 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0168%
Short position overnight fee 0.0086%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading